David A. Siegel Apellis Pharmaceuticals, Inc. Transaction History

Two Sigma Advisers, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$35.46 - $54.12 $1.09 Million - $1.66 Million	-30,600 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$30.74 - $49.16 $14.2 Million - $22.7 Million	-461,000 Reduced 93.78%	30,600 $1.45 Million
Q3 2021 Nov 15, 2021	SELL	$31.4 - $69.84 $4.15 Million - $9.24 Million	-132,300 Reduced 21.21%	491,600 $16.2 Million
Q2 2021 Aug 16, 2021	SELL	$40.9 - $64.9 $2.6 Million - $4.12 Million	-63,500 Reduced 9.24%	623,900 $39.4 Million
Q1 2021 May 17, 2021	SELL	$40.8 - $57.39 $864,959 - $1.22 Million	-21,200 Reduced 2.99%	687,400 $29.5 Million

Q4 2020 Feb 16, 2021	SELL	$30.79 - $57.2 $3.19 Million - $5.93 Million	-103,600 Reduced 12.76%	708,600 $40.5 Million
Q3 2020 Nov 16, 2020	SELL	$25.89 - $33.65 $2.82 Million - $3.67 Million	-109,000 Reduced 11.83%	812,200 $24.5 Million
Q2 2020 Aug 14, 2020	BUY	$24.8 - $38.49 $1.09 Million - $1.69 Million	44,000 Added 5.02%	921,200 $30.1 Million
Q1 2020 May 15, 2020	BUY	$17.91 - $44.33 $11.1 Million - $27.4 Million	617,200 Added 237.38%	877,200 $23.5 Million
Q4 2019 Feb 14, 2020	BUY	$22.1 - $30.8 $4.18 Million - $5.83 Million	189,300 Added 267.75%	260,000 $7.96 Million
Q3 2019 Nov 14, 2019	BUY	$24.09 - $32.18 $1.7 Million - $2.28 Million	70,700 New	70,700 $1.7 Million

337

111M

1.26M

1.14M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $4.21B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.